BR112017009471A2 - síntese de copanlisib e seu sal de di-hidrocloreto. - Google Patents

síntese de copanlisib e seu sal de di-hidrocloreto.

Info

Publication number
BR112017009471A2
BR112017009471A2 BR112017009471A BR112017009471A BR112017009471A2 BR 112017009471 A2 BR112017009471 A2 BR 112017009471A2 BR 112017009471 A BR112017009471 A BR 112017009471A BR 112017009471 A BR112017009471 A BR 112017009471A BR 112017009471 A2 BR112017009471 A2 BR 112017009471A2
Authority
BR
Brazil
Prior art keywords
copanlisib
synthesis
dihydrochloride salt
intermediate compounds
dihydrochloride
Prior art date
Application number
BR112017009471A
Other languages
English (en)
Other versions
BR112017009471B1 (pt
Inventor
Peters Jan-Georg
Stiehl Jürgen
Lovis Kai
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of BR112017009471A2 publication Critical patent/BR112017009471A2/pt
Publication of BR112017009471B1 publication Critical patent/BR112017009471B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Catalysts (AREA)

Abstract

a presente invenção está relacionada a um novo método de preparação de copanlisib e di-hidrocloreto de copanlisib, a novos compostos intermediários e ao uso dos novos compostos intermediários para a preparação do copanlisib.
BR112017009471-1A 2014-11-07 2015-11-05 Métodos para preparação de copanlisib e de seu sal de di-cloridrato, seus intermediários e seu uso BR112017009471B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192202.1 2014-11-07
EP14192202.1A EP3018131A1 (en) 2014-11-07 2014-11-07 Synthesis of copanlisib and its dihydrochloride salt
PCT/EP2015/075765 WO2016071426A1 (en) 2014-11-07 2015-11-05 Synthesis of copanlisib and its dihydrochloride salt

Publications (2)

Publication Number Publication Date
BR112017009471A2 true BR112017009471A2 (pt) 2018-01-02
BR112017009471B1 BR112017009471B1 (pt) 2023-02-28

Family

ID=51866060

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009471-1A BR112017009471B1 (pt) 2014-11-07 2015-11-05 Métodos para preparação de copanlisib e de seu sal de di-cloridrato, seus intermediários e seu uso

Country Status (34)

Country Link
US (1) US10035803B2 (pt)
EP (2) EP3018131A1 (pt)
JP (1) JP6691114B2 (pt)
KR (1) KR102562286B1 (pt)
CN (1) CN107074776B (pt)
AR (1) AR102568A1 (pt)
AU (1) AU2015341779B2 (pt)
BR (1) BR112017009471B1 (pt)
CA (1) CA2966796C (pt)
CL (1) CL2017001130A1 (pt)
CO (1) CO2017004533A2 (pt)
DK (1) DK3215507T3 (pt)
EA (1) EA031248B1 (pt)
ES (1) ES2716730T3 (pt)
HR (1) HRP20190527T8 (pt)
HU (1) HUE042794T2 (pt)
IL (1) IL251586B (pt)
JO (1) JO3487B1 (pt)
LT (1) LT3215507T (pt)
MX (1) MX365111B (pt)
MY (1) MY183123A (pt)
NZ (1) NZ730843A (pt)
PE (1) PE20170951A1 (pt)
PL (1) PL3215507T3 (pt)
PT (1) PT3215507T (pt)
RS (1) RS58494B1 (pt)
SG (1) SG11201702999XA (pt)
SI (1) SI3215507T1 (pt)
TR (1) TR201904346T4 (pt)
TW (1) TWI697494B (pt)
UA (1) UA118999C2 (pt)
UY (1) UY36396A (pt)
WO (1) WO2016071426A1 (pt)
ZA (1) ZA201703866B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
SG11201507265XA (en) 2013-04-08 2015-10-29 Bayer Pharma Aktiengesllschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
MX2017011635A (es) 2015-03-09 2018-02-09 Bayer Pharma AG Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
US10925880B2 (en) 2016-09-23 2021-02-23 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
TW565582B (en) * 2001-04-13 2003-12-11 Kaneka Corp Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them
ATE316085T1 (de) * 2001-08-15 2006-02-15 Du Pont Mit heterocyclen ortho-substituierte aryl amide zur bekämpfung wirbelloser schädlinge
ES2367141T3 (es) 2002-09-30 2011-10-28 Bayer Pharma Aktiengesellschaft Derivados de azol-pirimidina condensados.
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CA2713388C (en) * 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY156209A (en) 2009-11-04 2016-01-29 Novartis Ag Heterocyclic sulfonamide derivatives useful mek inhibitors
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Also Published As

Publication number Publication date
UA118999C2 (uk) 2019-04-10
US20170327505A1 (en) 2017-11-16
MY183123A (en) 2021-02-15
SI3215507T1 (sl) 2019-04-30
UY36396A (es) 2016-06-30
EP3215507A1 (en) 2017-09-13
MX2017005891A (es) 2017-06-30
KR20170078654A (ko) 2017-07-07
TW201625633A (zh) 2016-07-16
SG11201702999XA (en) 2017-05-30
JP6691114B2 (ja) 2020-04-28
MX365111B (es) 2019-05-23
CN107074776A (zh) 2017-08-18
PL3215507T3 (pl) 2019-08-30
CL2017001130A1 (es) 2018-01-19
HRP20190527T8 (hr) 2020-02-21
US10035803B2 (en) 2018-07-31
WO2016071426A1 (en) 2016-05-12
PE20170951A1 (es) 2017-07-13
AR102568A1 (es) 2017-03-08
KR102562286B1 (ko) 2023-08-02
CA2966796C (en) 2022-12-06
LT3215507T (lt) 2019-04-10
TR201904346T4 (tr) 2019-04-22
HUE042794T2 (hu) 2019-07-29
DK3215507T3 (en) 2019-04-15
RS58494B1 (sr) 2019-04-30
JO3487B1 (ar) 2020-07-05
AU2015341779B2 (en) 2020-02-27
EP3018131A1 (en) 2016-05-11
JP2017536352A (ja) 2017-12-07
TWI697494B (zh) 2020-07-01
EP3215507B1 (en) 2018-12-26
IL251586B (en) 2019-05-30
ZA201703866B (en) 2019-06-26
HRP20190527T1 (hr) 2019-05-17
EA031248B1 (ru) 2018-12-28
ES2716730T3 (es) 2019-06-14
CO2017004533A2 (es) 2017-07-19
PT3215507T (pt) 2019-03-29
BR112017009471B1 (pt) 2023-02-28
NZ730843A (en) 2022-12-23
CA2966796A1 (en) 2016-05-12
AU2015341779A1 (en) 2017-05-11
EA201790982A1 (ru) 2017-10-31
IL251586A0 (en) 2017-06-29
CN107074776B (zh) 2021-02-02

Similar Documents

Publication Publication Date Title
BR112017009470A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
BR112017009471A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
CO2017003955A2 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112016018654A2 (pt) Composições de silicato estabilizadas e seu uso como composições antiperspirantes
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
BR112019006030A2 (pt) formas cristalinas e de sal de compostos agonistas de ppar
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
PE20180219A1 (es) Procesos para preparar fluorocetolidos
EA201791645A1 (ru) Новые соли и полиморфы scy-078
BR112018012325A2 (pt) métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
BR112019002828A2 (pt) método de preparação de derivados de estireno substituído
CL2016002925A1 (es) Procedimiento mejorado para preparar ácidos crotónicos sustituidos
UY35715A (es) Proceso para preparar dronedarona y sales de la misma
BR112018072246A2 (pt) síntese de indazóis
BR112018072213A2 (pt) síntese de indazóis
BR112016016361A2 (pt) Composto e método para preparação
UY36284A (es) Método para la preparación de imidazopiridazinas sustituidas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 487/04 , C07D 233/24 , C07D 295/088

Ipc: C07D 487/04 (2006.01), C07D 233/24 (2006.01), C07D

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/11/2015, OBSERVADAS AS CONDICOES LEGAIS